Latest Genentech Stories
Fovista and Abicipar Pegol Will Need to be Priced Competitively to Current Agents to Garner Favorable Tier Placement, According to Findings from Decision Resources Group BURLINGTON, Mass.,
Several Emerging Therapies Will Expand Treatment Armamentarium for Unresectable Locally Advanced or Metastatic Gastric Cancer, According to Findings from Decision Resources Group BURLINGTON,
DUBLIN and MELBOURNE, Australia, Sept. 18, 2014 /PRNewswire/ -- Veterinary biologic therapy developer Nexvet Biopharma today announced the appointments of Dr.
- Calico to create a leading R&D facility in the San Francisco Bay Area focused on aging and age-related diseases, including neurodegeneration and cancer NORTH CHICAGO, Ill.
-- Roche to acquire InterMune for $74.00 per share -- BASEL, Switzerland, Aug. 24, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc.
Top Healthcare Talent, Companies and Brand Champions to be Honored September 18th New York, NY (PRWEB) August 20, 2014 The finalists are in for the sixth-annual
SUNNYVALE, Calif., Aug. 18, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has appointed Shawn Cline Tomasello as its Chief Commercial Officer. Ms.
Over Three-Quarters of Physicians View Ophthotech's Fovista as an Emerging Therapy with High Potential Value for Wet AMD, According to Findings from Decision Resources Group BURLINGTON, Mass.,
New PSA Inspires Everyone to Come Together in the Spirit of Collaboration and to Advance Cancer Research LOS ANGELES and NEW YORK, July 30, 2014 /PRNewswire-USNewswire/ -- Stand Up
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.